Combined therapy of dabrafenib and an anti-HER2 antibody-drug conjugate for advanced BRAF-mutant melanoma

CONCLUSION: These findings establish a preclinical foundation for the combined use of an anti-HER2 drug conjugate and a BRAF inhibitor in the treatment of BRAF-mutant cutaneous melanoma.PMID:38594618 | PMC:PMC11005275 | DOI:10.1186/s11658-024-00555-z

Source: Cellular and Molecular Biology Letters - April 9, 2024 Category: Biochemistry Authors: Weisong Li Chao Zheng Xi Xu Yujie Xia Kai Zhang Ao Huang Xinyu Zhang Yong Zheng Guofang Chen Shuyong Zhang Source Type: research